Company news
Arbutus Biopharma Corporation (NASDAQ:ABUS) news
Every Arbutus Biopharma Corporation press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 3
Arbutus Biopharma, X-Chem and Proteros biostructures Achieve First Milestone Under COVID-19 Discovery Research and License Agreement
December 7, 2021
Preliminary Data Shows that Arbutus’ Capsid Inhibitor, AB-836 is Generally Safe and Well-Tolerated and Provides Robust Antiviral Activity
December 1, 2021
Arbutus Biopharma Appoints Tram Tran, M.D. to its Board of Directors
November 11, 2021
Arbutus to Participate at Jefferies London Healthcare Conference
November 10, 2021
Arbutus Announces New Data on AB-729 in Late Breaker Poster Presentation at AASLD - The Liver Meeting®
November 10, 2021
Arbutus Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 4, 2021
Arbutus Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® 2021
November 1, 2021
Arbutus to Report Third Quarter 2021 Financial Results and Provide Corporate Update
October 21, 2021
Arbutus to Participate in October Investor Conferences
September 28, 2021
Arbutus Appoints Lisa M. Caperelli as Vice President, Investor Relations
September 21, 2021
Arbutus to Participate in Upcoming Investor Conferences
September 7, 2021
Arbutus Reports Second Quarter 2021 Financial Results and Provides Corporate Update
August 5, 2021
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
August 3, 2021
Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update
July 29, 2021
Arbutus Receives Authorization to Proceed with an Investigational New Drug Application (IND) for AB-729, its Proprietary Subcutaneously-Delivered RNAi Agent
July 7, 2021
Arbutus Biopharma and Vaccitech Announce Clinical Trial Collaboration Agreement to Evaluate RNAi Therapeutic, AB-729, in Combination with Immunotherapeutic, VTP-300, in Subjects with Chronic Hepatitis B Virus Infection
July 6, 2021
Arbutus Biopharma and Antios Therapeutics Announce Clinical Collaboration Agreement to Evaluate AB-729 in Combination with ATI-2173 in Subjects with Chronic Hepatitis B Virus Infection
June 29, 2021
Arbutus Announces New Data on AB-729 and AB-836 Programs with Presentation of Five Abstracts at the EASL International Liver Congress™ 2021 - All Selected for Best of ILC™
June 26, 2021
Arbutus Announces Multiple Abstracts Accepted for Oral and Poster Presentations at the EASL 2021 International Liver Congress in June
June 2, 2021
Arbutus Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 5, 2021
Arbutus to Report First Quarter 2021 Financial Results and Provide Corporate Update
April 28, 2021
Arbutus Biopharma, X-Chem and Proteros biostructures Enter into a Pan-Coronavirus Discovery Research and License Agreement
April 1, 2021
Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection
March 16, 2021
Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update
March 4, 2021
Arbutus to Participate at H.C. Wainwright Global Life Sciences Conference
March 2, 2021
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus
February 26, 2021
Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update
February 22, 2021
Arbutus Announces 2021 Corporate Objectives and Provides Financial Update
January 25, 2021
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
January 4, 2021
Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects
December 10, 2020
Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects
November 16, 2020
Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting
November 15, 2020
Arbutus to Present at Jefferies Virtual London Healthcare Conference
November 10, 2020
Arbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 5, 2020
Arbutus to Report Third Quarter 2020 Financial Results and Provide Corporate Update
October 29, 2020
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference
October 13, 2020
Arbutus to Participate in Virtual Fireside Chat at Chardan’s 4th Annual Genetic Medicines Conference
September 28, 2020
Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg
September 15, 2020
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright 22nd Annual Global Investment Conference
September 9, 2020
Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection
August 27, 2020
Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 7, 2020
Arbutus to Report Second Quarter 2020 Financial Results
July 29, 2020
Arbutus to Present at Jefferies Virtual Healthcare Conference
May 27, 2020
Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg
May 18, 2020
Arbutus to Present at UBS Virtual Global Healthcare Conference
May 12, 2020
Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections
May 11, 2020
Arbutus to Report First Quarter 2020 Financial Results
May 4, 2020
Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B
March 26, 2020
Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update
March 5, 2020
Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results
February 27, 2020